A combination vaccine is a mixture of two or more than two vaccines that could be administered separately, which is put into a single shot. The combination vaccine offers the same protection to children as the two vaccines administered separately, but with a few number of shots. Disease prevention and eradication of preventable diseases are eventual and instant goals of immunization and the method to achieve these goals is maintaining vaccine coverage. Vaccine coverage can be maintained by using combination vaccines, as they simplify the schedule of vaccination and reduce the number of injections required.
The development of combination vaccines for protection against multiple diseases was initiated by combining separate vaccines against tetanus, diphtheria, and pertussis into a single product. This combination of diphtheria, pertussis, and tetanus vaccines into a single product has been crucial for protection of children. Similarly, the combination of inactivated polio, hepatitis B, and Haemophilus influenzae vaccines has enabled the inclusion of these vaccines into recommended immunization schedules, by reducing the number of injections required. This has also increased the immunization compliance. However, numerous challenges are faced while developing these combinations including the abridged response to the Haemophilus influenzae vaccine when administered in combination. There is immediate need to expand the safety profile of the tetanus, diphtheria, and pertussis combination vaccine.
An important development in the field of combination vaccines was replacement of whole-cell pertussis antigens with less reactogenic acellular antigens. This paved the way for combining of tetanus, diphtheria, and acellular pertussis antigens with other routinely used vaccines such as inactivated Haemophilus influenzae vaccine, polio vaccine, and hepatitis B vaccine. Another significant combination vaccine that gives protection against more than one disease is the mumps, measles, and rubella (MMR) vaccine. A few examples of commonly used combination vaccines in children are: ProQuad, which combines MMR and varicella; Pediarix, which combines Hep B, DTaP, and IPV; Pentacel, which combines DTaP, IPV, and Hib; and Kinrix, which combines IPV and DTaP.
The global combination vaccines market is driven by increase in the prevalence of infectious diseases. Infectious diseases is one of the most leading causes of illnesses and deaths worldwide. In developing countries with weak health care infrastructure, influence of infectious diseases is even devastating, leading to reduced survival rates, particularly in children and hampering the economy. The increase in pediatric population is one of the primary drivers for the global combination vaccines market. With the increase in pediatric population, the demand for combination vaccines for immunization has increased, as infants are more susceptible to various infectious diseases due to their weak immune systems. Occurrence of viral infections and diseases such as polio, tetanus, diphtheria, smallpox, chickenpox, and measles has been observed to be high among children in developing countries. This is anticipated to drive the demand for combination vaccines during the forecast period. As scientists are developing and testing new vaccines to protect children from more diseases, more combination vaccines may become available in the near future. This would allow children to get additional protection with a fewer number of shots.
The global combination vaccines market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is projected to register a high CAGR during the forecast period, due to rising pediatric population and increasing awareness about vaccination in the region. Continuous efforts by market players and national organizations to promote the use of combination vaccines would drive the market in developed countries in the near future.
Key players operating in the global combination vaccines market include GlaxoSmithKline, Merck & Co., Inc., Sanofi Aventis, Pfizer, Inc., Novartis AG, and Takeda Pharmaceutical Company Limited.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.